Previous 10 | Next 10 |
New York City Mayor Bill de Blasio this afternoon said that the city will be distributing 500K rapid at-home COVID tests and 1M KN95 masks in the latest effort to curb the spread of the virus. The city is also increasing testing capacity by increasing hours at sites and adding more of them. I...
CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced to...
CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, ann...
CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced to...
Continuing its rise from Friday, shares of Cue Biopharma (NASDAQ:CUE) are up another 8% in premarket trading following data on its lead candidate CUE-101 for HPV+ head and neck cancer. The stock closed up 9.8% on Friday following release of the data. Shares are up 9.5% thi...
Creative Realities (NASDAQ:CREX) +91% industry merger creates powerful new digital signage leader EyePoint Pharmaceuticals EYPT +36% reports positive EYP-1901 data for treatment of wet AMD Bit Brother (NASDAQ:BTB) +20%. Oxbridge Re Holdings OXBR +15% on Q3 earnings. Cue Biophar...
Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells. Medicenna’s candidate for treating rGBM, MDNA55, has shown promising efficacy and safety data in its recently concluded phase II trial. MDNA11, an IL-2 s...
Monotherapy data further enhances confidence in CUE-101 potential as single agent therapeutic in the refractory/metastatic human papillomavirus positive head and neck squamous cell carcinoma (HPV+ HNSCC) setting Early CUE-101 combination data with KEYTRUDA ® (...
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, ann...
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced to...
News, Short Squeeze, Breakout and More Instantly...
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company anticipates annualized capital and workforce requirements to be reduced by approximately 25...
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and KEYTRUDA ® (pembrolizumab) Median overall survival (mOS) of 20.8 months in second...
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it will participate in two investor confe...